



---

## Applied DNA Sciences Ships First Commercial Order for DermalRx™

**STONY BROOK, N.Y., November 26, 2007/Business Wire/** -- Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN), a provider of DNA-based security solutions, today announced that it has shipped its first commercial order of DermalRx™. DermalRx is an ingredient that acts as an alternative to chemical peels in a new skin care product that is being manufactured under a top selling label of a large multinational company. This product is expected to be launched in Spring 2008.

“We are pleased at the speed with which we have been able to ramp up production, from pilot scale to commercial scale in just a few months,” commented Dr. James Hayward, President and CEO of APDN. “We anticipate additional orders of DermalRx, which will generate initial revenues for APDN. These revenues will assist APDN as it continues to pursue the implementation of its core SigNature DNA product line in a wide variety of applications where counterfeiting and piracy continue to threaten consumer health and safety.”

### **About Applied DNA Sciences, Inc.**

Applied DNA Sciences, Inc. provides botanical DNA encryption, embedment and authentication solutions that can help protect companies, governments and consumers from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion into physical locations and databases. APDN’s common stock is listed on the Over-The-Counter Bulletin Board under the symbol "APDN".

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-KSB, filed on January 16, 2007 and our subsequent quarterly reports on Form 10-QSB. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

SOURCE Applied DNA Sciences, Inc.

/CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848/  
/FCMN Contact: info@adnas.com /  
/Web site: <http://www.ADNAS.com> /